Therefore, we propose an alternative methodology to generating high-level evidence by using aggregated n-of-1 trials to assess the effectiveness of L-serine on symptoms in GRIN2B- NDD. The gene discussed is GRIN2B; the disease is Neurodevelopmental delay.